COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01086462
Recruitment Status : Completed
First Posted : March 15, 2010
Last Update Posted : July 18, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.

Condition or disease Intervention/treatment Phase
Asthma Drug: GSK2239633 Phase 1

Detailed Description:
The different shapes of the pharmacokinetic (PK) profiles following administration of GSK2239633 in rat and dog make it difficult to reliably predict the human PK profile. This microdose study will provide an early readout on the distribution and clearance profile of the drug in man and will be used to model potential clinical oral doses. The study will be conducted using an open-label, single dose design in one group of healthy male volunteers. Each subject will receive a single intravenous infusion of 100ug GSK2239633 (containing approximately 10kBq of [14C]-GSK2239633), administered over 15 minutes. Subjects will attend for a screening visit within 30 days prior to Day 1 and receive a single dose infusion of study drug on Day 1. Blood and urine samples will be taken over 48 hours for pharmacokinetic and total radioactivity analysis, and safety and tolerability will be monitored. Subjects will be discharged on Day 3 and a follow-up telephone call will be made 4-10 days post-dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects
Actual Study Start Date : January 21, 2010
Actual Primary Completion Date : February 22, 2010
Actual Study Completion Date : February 22, 2010

Arm Intervention/treatment
Experimental: GSK2239633
Single dose infusion of study drug over 15 minutes
Drug: GSK2239633
100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633




Primary Outcome Measures :
  1. Pharmacokinetics (AUC0-inf, Cmax, AUC0-t, t1/2, clearance, volume of distribution) of [14C]-GSK2239633 and total drug-related material [ Time Frame: 48 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects are defined as individuals who in the opinion of the Investigator are free from clinically significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, endocrine, neurological and psychiatric disease or malignancy as determined by medical history, physical examination, laboratory studies, and other tests (including ECG). Subjects with values outside the normal range which are deemed to be clinically relevant should always be excluded from enrollment.
  • Male between 18 and 50 years of age inclusive, at the time of signing the informed consent.
  • Subject must agree to use one of the contraception methods listed in Section 8.1. of the protocol. This criterion must be followed from the time of screening until 90 days after the follow up
  • Body weight >or= 50 kg and BMI within range 18.5-29.9 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
  • Single QTcF <450 msec; or QTcF <480 msec in subjects with Bundle Branch Block
  • Lifelong non-smokers or ex-smokers of greater than 6 months and <5 pack year history. Pack years = (cigarettes per day smoked/20) x number of years smoked.
  • AST, ALT, alkaline phosphatase and bilirubin <or=1.5 ULN (isolated bilirubin >1.5 x ULN acceptable if bilirubin is fractionated and direct bilirubin <35%)

Exclusion Criteria:

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody within 3 months of screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities
  • A positive pre-study drug/alcohol screen
  • A positive test for HIV antibody
  • History of regular alcohol consumption within 6 months of study defined as an average weekly intake of >12 units/week for males. One unit is equivalent to 8g of alcohol; a half-pint (~250ml) of beer, 1 glass (100ml) of wine or 1 (35 ml) measure of spirits.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (including snuff, nicotine-containing gum) within 6 months prior to screening
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to first dosing: 60 days, 5 half-lives or twice the duration of the biological effect of investigational product (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Participation in a clinical trial involving administration of 14C-labelled compounds within last 12 months
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days or 5 half-lives prior to the first dose of study medication, unless in the opinion of the Investigator and Medical Monitor the medication will not interfere with study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • Unwillingness or inability to follow procedures outlined in the protocol
  • Subject is mentally or legally incapacitated
  • A calculated creatinine clearance (Cockroft and Gault formula) of <90 mL/min
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01086462


Locations
Layout table for location information
Netherlands
GSK Investigational Site
Zuidlaren, Netherlands, 9471 GP
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Additional Information:
Study Data/Documents: Annotated Case Report Form  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Statistical Analysis Plan  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register
Dataset Specification  This link exits the ClinicalTrials.gov site
Identifier: 114041
For additional information about this study please refer to the GSK Clinical Study Register

Publications:
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01086462    
Other Study ID Numbers: 114041
First Posted: March 15, 2010    Key Record Dates
Last Update Posted: July 18, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Keywords provided by GlaxoSmithKline:
GSK2239633
RADIOLABEL
PHARMACOKINETICS
INTRAVENOUS
MICRODOSE